STEVEN KATZ: Open Payments
NPI 1679502140 · HARTFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,641 in 211 payments from 21 companies in 2025. Trend: 2023 $3,251 · 2024 $3,418 · 2025 $3,641
Food & beverage: $3,634Education: $7
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $575 |
| Teva Pharmaceuticals USA, Inc. | 24 | $484 |
| Neurocrine BioSciences, Inc. | 18 | $288 |
| E.R. Squibb & Sons, L.L.C. | 15 | $273 |
| Corium, LLC | 23 | $273 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $259 |
| Otsuka America Pharmaceutical, Inc. | 13 | $245 |
| Alkermes, Inc. | 9 | $230 |
| Janssen Pharmaceuticals, Inc | 8 | $162 |
| Axsome Therapeutics, Inc. | 6 | $159 |
Products named: VRAYLAR, REXULTI, INGREZZA, COBENFY, Azstarys, AUSTEDO XR, CAPLYTA, ARISTADA.
Industry payments across CT — which companies pay providers there.
